Clinical trials: Cyclophosphamide, open to volunteers
Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG)
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
This single-arm, open-label investigator-initiated trial (IIT) evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05 in patients with autoimmune neurological diseases, including Multiple…
- Conditions
- Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Autoimmune Encephalitis (AE)
- Trial name
- NCT07337785
- Testing
- CD19/BCMA-targeted CAR-T cells, Lymphodepleting Conditioning
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Lupus Nephritis
Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children
The objective of this study is to assess the efficacy and safety of rituximab combining with low-dose mycophenolate mofetil in the induction therapy of proliferative lupus nephritis in children.
- Trial name
- NCT07675291
- Testing
- rituximab, Mycophenolate Mofetil (MMF) Treatment, Cyclophosphamide
- Volunteers
- 112 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Neurological Autoimmune Diseases
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY001N cell injection in the treatment of patients with relapsed/refractory…
- Trial name
- NCT07265206
- Testing
- HY001N cell injection
- Volunteers
- 15 people
- Sponsor
- Juventas Cell Therapy Ltd.
AML, MDS
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide…
- Conditions
- AML, MDS, Acute Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07493538
- Testing
- Treosulfan, Fludarabine, Total Body Irradiation
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
TNBC - Triple-Negative Breast Cancer
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR） of treatment of TNBC breast cancer with neoadjuvant chemotherapy…
- Trial name
- NCT07351487
- Testing
- Neoadjuvant chemotherapy combined with Sintilimab and Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Melanoma
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Background: Cell therapy is an experimental cancer therapy. It takes young tumor infiltrating lymphocytes (Young TIL) cells from a person s tumors and grows them in a lab. Then they are returned to the person.
- Trial name
- NCT02621021
- Testing
- young TIL, Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Richter Syndrome
Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome
This is a national clinical trial, multicentric (28 centers), non-randomized phase 2 study. Population: Patients with previously untreated Richter's syndrome (RS), defined as the occurrence of an aggressive lymphoma (of diffuse…
- Trial name
- GLORIFY (NCT06186648)
- Testing
- Glofitamab + Obinutuzumab
- Where
- 23 sites in France
- Volunteers
- 40 people
- Sponsor
- French Innovative Leukemia Organisation
Soft Tissue Sarcoma
Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities
Pediatric soft tissue sarcomas (STS) are a group of malignant tumors originating from primitive mesenchymal tissues and account for approximately 7% of childhood cancers.
- Trial name
- NCT07888114
- Testing
- Entinostat, VAC/VTC chemotherapy
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Beijing Tongren Hospital
DLBCL, Diffuse Large B Cell Lymphoma
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy, Australia and New Zealand, in elderly patients with untreated diffuse large B-cell lymphoma.
- Trial name
- POLAR BEAR (NCT04332822)
- Testing
- R-pola-mini-CHP, R-mini-CHOP
- Where
- 69 sites in Australia, Denmark and 5 more
- Volunteers
- 300 people
- Sponsor
- Nordic Lymphoma Group
SLE - Systemic Lupus Erythematosus, Systemic Sclerosis
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
This is a single-arm, open-label, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with autoantibody-mediated autoimmune…
- Conditions
- SLE - Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07596680
- Testing
- RD06-05 CAR-T Cell Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a multicenter, randomized, controlled, open-label Phase III clinical trial, aimed at evaluating the efficacy and safety of BEBT-908 combined with rituximab (R) compared to investigator-selected standard chemotherapy…
- Trial name
- NCT06792253
- Testing
- Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection
- Where
- China
- Volunteers
- 416 people
- Sponsor
- BeBetter Med Inc
Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS
Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
This is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)…
- Conditions
- Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes, Pineoblastoma
- Trial name
- IMPACT (NCT06193759)
- Testing
- Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA), Group A Standard-of-Care Backbone Therapy, Group B Salvage Backbone Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's National Research Institute
Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
- Trial name
- NCT07510802
- Testing
- Dual-target CAR-NK cells, Lymphodepleting, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Pediatric Cancer, Li-Fraumeni Syndrome
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.
- Conditions
- Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations
- Trial name
- NCT06088030
- Testing
- Arsenic trioxide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yang Li
Breast Cancer
Immunomonitoring of Breast Cancer Patients During Systemic Treatment
This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe…
- Trial name
- IMMUNE CAPTURE (NCT04925856)
- Testing
- blood sample
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Georges Francois Leclerc
Amyloid Light Chain (AL) Amyloidosis
Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis
Amyloid light chain (AL) amyloidosis is a rare disease caused by abnormal plasma cells producing misfolded light chain proteins that deposit in organs, leading to organ dysfunction and failure.
- Trial name
- NCT07793422
- Testing
- Etentamig, Daratumumab, Cyclophosphamide
- Volunteers
- 370 people
- Sponsor
- AbbVie
Advanced Hepatocellular Carcinoma (HCC)
Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
The goal of this open-label, single-arm phase I/II clinical trial is to evaluate the feasibility, safety, and anti-tumor efficacy of the autologous neoantigen-specific T-cell therapy (iNeo-Vac-T01) in patients with advanced…
- Trial name
- NCT07123545
- Testing
- iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine, iNeo-Vac-T01 Personalized T Cell Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer.
- Conditions
- Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
- Trial name
- DNADalHR (NCT06970912)
- Testing
- Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy, Taxane-Based Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Peking University People's Hospital
Advanced Melanoma, Melanoma Metastatic
NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
A single center, dose escalaion, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1 TCR)-directed T cells in combination with…
- Conditions
- Advanced Melanoma, Melanoma Metastatic, Sarcoma
- Trial name
- LauT1 (NCT06889766)
- Testing
- NY-ESO-1 TCR redirected autologous T cell product, Low-dose irradiation, Non-myeloablative lymphodepleting chemotherapy
- Where
- 2 sites in Switzerland
- Volunteers
- 9 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Clear Cell Renal Cell Carcinoma
Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01)
A Single-Arm, Open-Label, Interventional Study to Evaluate the Efficacy of HS-IT101 Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy After Lymphodepleting Preconditioning with Fludarabine and Cyclophosphamide and…
- Trial name
- NCT07770802
- Testing
- Cyclophosphamid, Fludarabine, Interleukin 2 subcutaneous injection
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Hangzhou Huasai Biomedicine Co., Ltd.